ABIDE项目:基于生物标志物预测轻度认知障碍患者进展为痴呆的风险模型
该研究基于ABIDE项目,纳入525例轻度认知障碍患者,构建基于年龄、性别、MMSE评分及MRI和脑脊液生物标志物的Cox预后模型,预测1年和3年进展为阿尔茨海默病痴呆或任何痴呆的风险,并在ADNI2中外部验证模型稳健。
要点
- 仅用年龄、性别和MMSE即可区分3年进展风险(26%-76%),生物标志物可进一步分层。
- MRI和CSF生物标志物异常者3年进展风险达82%-89%,双异常达89%。
- 双正常者3年进展风险仅4%,支持生物标志物用于个体化风险沟通。
核心结论
- 基于生物标志物的预后模型有助于在个体水平确定MCI患者进展为AD痴呆或任何痴呆的风险,支持临床决策和生物标志物的日常应用。
研究设计与样本
- 本研究为ABIDE项目的一部分,纳入阿姆斯特丹痴呆队列中525例MCI患者,基线访视时间为1997年9月1日至2014年8月31日。
- 采用Cox比例风险回归构建预后模型,纳入患者特征(年龄、性别、MMSE评分)、MRI生物标志物(海马体积、标准化全脑体积)、CSF生物标志物(β淀粉样蛋白1-42、tau)及联合生物标志物。
- 主要终点为1年和3年后AD痴呆及任何类型痴呆,并在ADNI2中进行外部验证。
主要发现
- 525例患者中210例(40.0%)为女性,平均(SD)年龄67.3(8.4)岁。
- 仅基于年龄、性别和MMSE,3年进展为AD痴呆风险从年轻男性MMSE 29分的26%(95% CI 19%-34%)至老年女性MMSE 24分的76%(95% CI 65%-84%);1年风险从6%(95% CI 4%-9%)至24%(95% CI 18%-32%)。
- MRI异常时3年和1年进展风险分别为86%(95% CI 71%-95%)和27%(95% CI 17%-41%);CSF异常时分别为82%(95% CI 73%-89%)和26%(95% CI 20%-33%);两者均异常时分别为89%(95% CI 79%-95%)和26%(95% CI 18%-36%)。
- MRI正常时3年和1年进展风险分别为18%(95% CI 13%-27%)和3%(95% CI 2%-5%);CSF正常时分别为6%(95% CI 3%-9%)和1%(95% CI 0.5%-2%);两者均正常时分别为4%(95% CI 2%-7%)和0.5%(95% CI 0.2%-1%)。
- 预测任何类型痴呆的模型预后价值在相同数量级但略低,外部验证显示模型高度稳健。
关键数值与推荐
- MRI异常时3年进展为AD痴呆风险86%(95% CI 71%-95%),CSF异常时82%(95% CI 73%-89%),两者均异常时89%(95% CI 79%-95%)。
- MRI正常时3年进展风险18%(95% CI 13%-27%),CSF正常时6%(95% CI 3%-9%),两者均正常时4%(95% CI 2%-7%)。
临床怎么用
- 临床可结合患者年龄、性别、MMSE评分及MRI/CSF生物标志物结果,个体化评估MCI患者1年和3年进展为痴呆的风险。
- 生物标志物正常可提示低进展风险,异常则提示高进展风险,有助于医患沟通和临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Biomarkers do not determine conversion to Alzheimer disease (AD) perfectly, and criteria do not specify how to take patient characteristics into account. Consequently, biomarker use may be challenging for clinicians, especially in patients with mild cognitive impairment (MCI). OBJECTIVE: To construct biomarker-based prognostic models that enable determination of future AD dementia in patients with MCI. DESIGN, SETTING, AND PARTICIPANTS: This study is part of the Alzheimer's Biomarkers in Daily Practice (ABIDE) project. A total of 525 patients with MCI from the Amsterdam Dementia Cohort (longitudinal cohort, tertiary referral center) were studied. All patients had their baseline visit to a memory clinic from September 1, 1997, through August 31, 2014. Prognostic models were constructed by Cox proportional hazards regression with patient characteristics (age, sex, and Mini-Mental State Examination [MMSE] score), magnetic resonance imaging (MRI) biomarkers (hippocampal volume, normalized whole-brain volume), cerebrospinal fluid (CSF) biomarkers (amyloid-β1-42, tau), and combined biomarkers. Data were analyzed from November 1, 2015, to October 1, 2016. MAIN OUTCOMES AND MEASURES: Clinical end points were AD dementia and any type of dementia after 1 and 3 years. RESULTS: Of the 525 patients, 210 (40.0%) were female, and the mean (SD) age was 67.3 (8.4) years. On the basis of age, sex, and MMSE score only, the 3-year progression risk to AD dementia ranged from 26% (95% CI, 19%-34%) in younger men with MMSE scores of 29 to 76% (95% CI, 65%-84%) in older women with MMSE scores of 24 (1-year risk: 6% [95% CI, 4%-9%] to 24% [95% CI, 18%-32%]). Three- and 1-year progression risks were 86% (95% CI, 71%-95%) and 27% (95% CI, 17%-41%) when MRI results were abnormal, 82% (95% CI, 73%-89%) and 26% (95% CI, 20%-33%) when CSF test results were abnormal, and 89% (95% CI, 79%-95%) and 26% (95% CI, 18%-36%) when the results of both tests were abnormal. Conversely, 3- and 1-year progression risks were 18% (95% CI, 13%-27%) and 3% (95% CI, 2%-5%) after normal MRI results, 6% (95% CI, 3%-9%) and 1% (95% CI, 0.5%-2%) after normal CSF test results, and 4% (95% CI, 2%-7%) and 0.5% (95% CI, 0.2%-1%) after combined normal MRI and CSF test results. The prognostic value of models determining any type of dementia were in the same order of magnitude although somewhat lower. External validation in Alzheimer's Disease Neuroimaging Initiative 2 showed that our models were highly robust. CONCLUSIONS AND RELEVANCE: This study provides biomarker-based prognostic models that may help determine AD dementia and any type of dementia in patients with MCI at the individual level. This finding supports clinical decision making and application of biomarkers in daily practice.
引用
- van Maurik IS, Zwan MD, Tijms BM, et al. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurol. 2017. PMID: 29049480. doi:10.1001/jamaneurol.2017.2712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。